A small clinical trial of siltuximab in patients with platinum-resistant ovarian cancer further demonstrated periods of disease stabilization in approximately 40% of patients, and significant declines in plasma levels of relevant pro-tumorigenic cytokines including VEGF. This evidence concerns the gene VEGFA and ovarian cancer.